Trials / Unknown
UnknownNCT04197323
Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran
Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran of Phase II Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, positive-control, multicenter, multiple-dose, dose-escalation phase II trial
Detailed description
A randomized, positive-control, multicenter, multiple-dose, dose-escalation phase II trial. The trial was divided into 4 dose groups: the positive drug Kaishi 10 μg group and the alprostadil liposome for injection 40μg, 80μg, 120μg group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alprostadil liposomes for injection | 40ug,once a day,continuous administration for 2 weeks |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2021-06-01
- Completion
- 2021-06-01
- First posted
- 2019-12-13
- Last updated
- 2019-12-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04197323. Inclusion in this directory is not an endorsement.